Zobrazeno 1 - 10
of 59
pro vyhledávání: ''
Autor:
Lash, T L1,2,3 tlash@bu.edu, Pedersen, L2, Cronin-Fenton, D2, Ahern, T P1, Rosenberg, C L3, Lunetta, K L4, Silliman, R A3, Hamilton-Dutoit, S5, Garne, J P6, Ewertz, M7, Sørensen, H T1,2, Sørensen, H T (AUTHOR)
Publikováno v:
British Journal of Cancer. 8/19/2008, Vol. 99 Issue 4, p616-621. 6p. 3 Charts.
Publikováno v:
British Journal of Cancer. 4/10/2007, Vol. 96 Issue 7, p1025-1029. 5p. 1 Diagram, 3 Charts.
Autor:
Yu, Ke-da, Di, Gen-hong, Wu, Jiong, Lu, Jin-song, Shen, Kun-wei, Liu, Guang-yu, Shen, Zhen-zhou, Shao, Zhio-Ming
Publikováno v:
Journal of Cancer Research & Clinical Oncology; Dec2008, Vol. 134 Issue 12, p1347-1354, 8p, 3 Charts, 4 Graphs
Autor:
Xavier Gonzalez, Miguel Caballero, Carlos Caso, Albert Biete, Araceli Rodriguez, G. Zanon, Juan J. Grau
Publikováno v:
Annals of Surgical Oncology
Background Many women covered by the Spanish public health system also have an extra private insurance policy for gynecological examinations and routine annual mammography. We retrospectively analyzed the long-term survival rates in these patients wh
Autor:
Haruhiko Fukuda, Seiki Takashima, Takashi Fukutomi, Hiroji Iwata, Jiro Ando, Kenichi Inoue, Takayuki Kinoshita, Kenichi Nakamura, Kenjiro Aogi, Tadahiko Shien, Taro Shibata
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose A prospective randomized clinical trial was conducted to evaluate the efficacy of tamoxifen plus doxorubicin and cyclophosphamide compared to tamoxifen plus tegafur-uracil as an adjuvant therapy to treat node-positive premenopausal breast can
Autor:
Gunnar Mellgren, Sara Gandini, Andrea Decensi, Jennifer Gjerde, Aliana Guerrieri-Gonzaga, Line L. Haugan Moi, Ernst A. Lien, Valentina Aristarco
Publikováno v:
Breast Cancer Research and Treatment
Tamoxifen dosage is based on the one-dose-fits-all approach. The anticancer effect of tamoxifen is believed to be due to the metabolites, 4-hydroxytamoxifen (4OHtam), and 4-hydroxy-N-desmethyltamoxifen (4OHNDtam/endoxifen). These demethylated metabol
Autor:
Johan Ahlgren, Irma Fredriksson, Malin Sund, John Weinman, Antonis Valachis, Lars Holmberg, Hans Garmo
Publikováno v:
Breast Cancer Research and Treatment
Valachis, A, Garmo, H, Weinman, J, Fredriksson, I, Ahlgren, J, Sund, M & Holmberg, L 2016, ' Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality : a population-based study ', Breast Cancer Research and Treatment, vol. 159, pp. 293–303 . https://doi.org/10.1007/s10549-016-3928-3
Valachis, A, Garmo, H, Weinman, J, Fredriksson, I, Ahlgren, J, Sund, M & Holmberg, L 2016, ' Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality : a population-based study ', Breast Cancer Research and Treatment, vol. 159, pp. 293–303 . https://doi.org/10.1007/s10549-016-3928-3
The purpose of the study was to investigate whether the concomitant use of selective serotonin reuptake inhibitors (SSRI) with tamoxifen influences the risk of death due to breast cancer, and we also investigated the association between SSRI use and
Autor:
Paul E. Goss
Publikováno v:
Breast Cancer Research and Treatment
Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer. Third-generation aromatase inhibitors, such as letrozole, provide a new option for extended adjuvant hormonal therapy after 5
Autor:
Anke Thomas, Sherko Kümmel, Stefan Paepke, Marion Kiechle-Bahat, Ralf Ohlinger, Nadia Harbeck, Mathias Warm, Volker R. Jacobs
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 133(12):905-916
Several large, well-controlled clinical trials have now established that the aromatase inhibitors (AIs), including letrozole, anastrozole, and exemestane, are more effective than tamoxifen when used as adjuvant endocrine therapy in postmenopausal wom
Publikováno v:
European Journal of Nutrition
Purpose Tamoxifen has been used for the treatment of estrogen receptor (ER)-positive breast cancers and in women who are at an increased risk of breast cancer. Acquired resistance to this drug and its toxicity still pose a clinically significant prob